Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Italy
Italy- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
804 trials match your criteria
Recruiting
Non-small cell lung cancer stage I
RecruitingInvestigational
A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer
Investigational
- Disease:Non-small cell lung cancer stage I
- Substances:Mrna-4157Pembrolizumab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Mrna-4157
Recruiting
Systemic lupus erythematosus
RecruitingRegistered drugNo placebo
Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus
Registered drugNo placebo
- Disease:Systemic lupus erythematosus
- Substances:Anifrolumab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Anifrolumab
Recruiting
Psoriatic arthropathy
RecruitingInvestigational
Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
Investigational
- Disease:Psoriatic arthropathy
- Substances:Zasocitinib
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Zasocitinib
Recruiting
Non-small cell lung cancer
RecruitingInvestigationalNo placebo
A study to evaluate the safety and effectiveness of HLX43 in patients with advanced non-small cell lung cancer
InvestigationalNo placebo
- Disease:Non-small cell lung cancer
- Substances:HLX43
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:HLX43
Recruiting
Colorectal cancer metastatic
RecruitingRegistered drugNo placebo
Study of Sotorasib, Panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.
Registered drugNo placebo
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabCalcium Folinate+4
Countries:Italy
Italy- Participants:18–64 years
- Substances:Bevacizumab
Recruiting
Non-small cell lung cancer+1
RecruitingRegistered drugNo placebo
Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC
Registered drugNo placebo
- Disease:Non-small cell lung cancerNon-small cell lung cancer metastatic
- Substances:CarboplatinInfliximab+5
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Carboplatin
Recruiting
Sjogren's syndrome
RecruitingInvestigationalNo placebo
A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time
InvestigationalNo placebo
- Disease:Sjogren's syndrome
- Substances:Dazodalibep
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Dazodalibep
Recruiting
Uveal melanoma
RecruitingInvestigationalNo placebo
A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread
InvestigationalNo placebo
- Disease:Uveal melanoma
- Substances:Darovasertib
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Darovasertib
Recruiting
Colorectal cancer metastatic
RecruitingRegistered drugNo placebo
A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer
Registered drugNo placebo
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabFluorouracil+3
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
Recruiting
Migraine
RecruitingRegistered drug
Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks
Registered drug
- Disease:Migraine
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Recruiting
Migraine
RecruitingRegistered drug
Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients
Registered drug
- Disease:Migraine
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins